BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 1926878)

  • 1. [The treatment of metastasizing breast carcinoma using antiestrogens].
    Pienkowski T; Palucka-Bartoszewicz A; Pienkowska F; Zborzil J; Schneider J
    Wien Med Wochenschr; 1991; 141(13):294, 297-300. PubMed ID: 1926878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tamoxifen in the management of advanced breast carcinoma in Nigerian women.
    Senbanjo RO; Ihekwaba FN; Ajayi OO
    West Afr J Med; 1990; 9(1):44-9. PubMed ID: 1702986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antiestrogens: a new endocrine treatment possibility in metastasizing breast neoplasms. Experiences of the Swiss Cooperative Cancer Study Group with tamoxifen].
    Jungi WF; Alberto P; Wagenknecht L; Cavalli F; Martz G; Brunner KW
    Schweiz Med Wochenschr; 1978 Aug; 108(34):1317-21. PubMed ID: 694481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hormone therapy of metastasizing breast cancer with tamoxifen].
    Köhler A; Noss W; Dobberstein N; Stoltmann R; Pohl J
    Z Gesamte Inn Med; 1986 Jan; 41(1):6-9. PubMed ID: 3953121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tamoxifen versus ethinyl estradiol in the treatment of postmenopausal women with advanced breast cancer.
    Beex L; Pieters G; Smals A; Koenders A; Benraad T; Kloppenborg P
    Cancer Treat Rep; 1981; 65(3-4):179-85. PubMed ID: 7237448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tamoxifen-treated breast carcinoma patients and the risk of acute myocardial infarction and newly-diagnosed angina.
    Bradbury BD; Lash TL; Kaye JA; Jick SS
    Cancer; 2005 Mar; 103(6):1114-21. PubMed ID: 15712362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endometrial carcinoma associated with breast carcinoma: low incidence with tamoxifen use.
    Cuenca RE; Giachino J; Arredondo MA; Hempling R; Edge SB
    Cancer; 1996 May; 77(10):2058-63. PubMed ID: 8640670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
    Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
    Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical evaluation of the antioestrogenic agent tamoxifen in the treatment of metastatic breast cancer (author's transl)].
    Szepesi T; Czech W
    Wien Klin Wochenschr; 1978 Feb; 90(4):133-41. PubMed ID: 625990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lonidamine versus high-dose tamoxifen in progressive, advanced renal cell carcinoma: results of an ongoing randomized phase II study.
    Stahl M; Schmoll E; Becker H; Schlichter A; Hoffmann L; Wagner H; Possinger K; Müller W; Köllermann M; Weidenhammer W
    Semin Oncol; 1991 Apr; 18(2 Suppl 4):33-7. PubMed ID: 2031196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of tamoxifen in the long-term treatment and prevention of breast cancer.
    Jordan VC
    Oncology (Williston Park); 1988 Sep; 2(9):19-28. PubMed ID: 3079292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A comparison of two doses of tamoxifen in patients with advanced breast cancer: 20 mg/day versus 40 mg/day].
    Takatsuka Y; Yayoi E; Inaji H; Aikawa T
    Gan To Kagaku Ryoho; 1989 May; 16(5):2093-7. PubMed ID: 2658841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The incidence of subsequent endometrial carcinoma with tamoxifen use in patients with primary breast carcinoma.
    Katase K; Sugiyama Y; Hasumi K; Yoshimoto M; Kasumi F
    Cancer; 1998 May; 82(9):1698-703. PubMed ID: 9576291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The results of a comparative clinical study of the antiestrogenic preparations toremifene and tamoxifen in locally advanced and disseminated breast cancer].
    Konstantinova MM; Gershanovich MA
    Vopr Onkol; 1990; 36(10):1182-6. PubMed ID: 2147527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Tamoxifen adjuvant delays early breast cancer. Results of a cooperative randomized trial].
    Delozier T; Switsers O; Génot JY; Ollivier JM; Héry M; Namer M; Frenay M; Kerbrat P; Julien JP; Naja A; Janvier M; Macé-Lesec'h J
    Bull Cancer; 1997 Jan; 84(1):25-30. PubMed ID: 9180855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anti-oestrogen treatment of metastasising carcinoma of the breast (author's transl)].
    Henningsen B; Amberger H
    Dtsch Med Wochenschr; 1977 May; 102(19):713-6. PubMed ID: 870301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antiestrogens in the treatment of advanced breast cancer].
    Płuzańska A; Smiałowska A; Stempczyńska J; Wator A
    Pol Tyg Lek; 1989 Feb 13-20; 44(7-8):191-4. PubMed ID: 2813178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: evidence from metastatic subgroups and a test of functional ability.
    Mouridsen H; Sun Y; Gershanovich M; Perez-Carrion R; Becquart D; Chaudri-Ross HA; Lang R
    Oncologist; 2004; 9(5):489-96. PubMed ID: 15477633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced age and adjuvant tamoxifen prescription in early-stage breast carcinoma patients.
    Blackman SB; Lash TL; Fink AK; Ganz PA; Silliman RA
    Cancer; 2002 Dec; 95(12):2465-72. PubMed ID: 12467058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.